Your session is about to expire
← Back to Search
Genetic Testing
Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care (OPTEC Trial)
N/A
Waitlist Available
Led By Paul Goodfellow
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
No Placebo-Only Group
Summary
This trial will test if universal screening for DNA mismatch repair deficiency can help guide treatment strategies for endometrial cancer patients.
Eligible Conditions
- Colorectal Cancer
- Uterine Cancer
- Endometrial Adenocarcinoma
- Family
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of endometrial cancer patients with Lynch syndrome
Incidence of tumors with microsatellite instability and/or somatic POLE mutations
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Comprehensive LS genetic testingExperimental Treatment4 Interventions
Testing for inherited forms of cancer and tumor sequencing
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,958 Previous Clinical Trials
41,111,578 Total Patients Enrolled
1 Trials studying Family
1,000 Patients Enrolled for Family
Ohio State University Comprehensive Cancer CenterLead Sponsor
342 Previous Clinical Trials
292,205 Total Patients Enrolled
Paul GoodfellowPrincipal InvestigatorOhio State University Comprehensive Cancer Center
1 Previous Clinical Trials